natgillin/translations-raw huggingface dataset:
wherein R1 is as defined for the compound of formula (IIb), with a chiral amine of formula (Vb) 
OH uso PH gdje je RI kao što je definiran za formulu (II), s kiralnim aminom formule (V)
The molecule for use according to claim 12, wherein said anti-cancer agent is sorafenib. 
Molekula za upotrebu u skladu s patentnim zahtjevom 12, naznačena time, da je navedeno sredstvo protiv raka sorafenib.
At block 1350, a function that approximates the calibration values across a plurality of fractional concentrations is determined. 
HR P20191300 T1 utvrđivanja funkcije koja približno određuje odgovarajuće kalibracijske vrijednosti za točke podataka za kalibraciju u nizu frakcionalnih koncentracija.
The method according to claim 1, wherein the acid catalyst used in the reaction may be a free acid catalyst or immobilised on a support. 
9. - Metoda prema bilo kojem od patentnih zahtjeva 1 do 8, naznačeno time da kiseli katalizator korišten u reakciji može biti katalizator sa slobodnom kiselinom ili nanesen na nosač.
Preferably such lozenges are characterised in that 50-90 wt %, more preferably 55-85 wt %, and most preferably 60-80 wt % of component (ii) consists of: 
Poželjno takve tablete je karakteristično da se 50-90 mas.%, poželjnije 55-85 mas.%, 1 najpoželjnije 60-80 mas.% komponente (ii) sastoji od:
The compound or pharmacologically acceptable salt thereof according to claim 7, wherein Het is a group represented by the formula: which may be substituted with 1 to 3 substituents selected from Substituent Group A4, wherein R6 and R7 are the same or different and each represent a substituent selected from Substituent Group A4, X3 is as defined in claim 7, and nc represents an integer of 0 to 2. 
Spoj ili njegova farmakološki prihvatljiva sol u skladu s patentnim zahtjevom 7, naznačen time, da je Het skupina prikazana formulom: [image] koja se može supstituirati s 1 do 3 supstituenta odabranih iz skupine supstituenata A4, pri čemu su R6 i R7 jednaki ili različiti, a svaki predstavlja supstituent odabran iz skupine supstituenata A4, X3 je definiran jednako kao u patentnom zahtjevu 7, a nC predstavlja cijeli broj u rasponu od 0 do 2.
combining a therapeutically effective amount of the anamorelin monohydrochloride of Embodiment 1, 2, 3, or 29, or the composition of Embodiment 12, with one or more pharmaceutically acceptable excipients to form a mixture; and 
4. - Farmaceutski sastav koji sadrži: a) terapeutski efikasnu količinu anamorelin monohidroklorida prema patentnim zahtjevima 1, 2 ili 3; 1 b) jedan ili više farmaceutski prihvatljivih ekscipijenata.
Such excipients must be compatible with the other ingredients of the formulation and not deleterious to the recipient thereof and are well known to the skilled artisan, see e.g. 
Takve pomoćne tvari trebaju biti kompatibilne s drugim sastojcima formulacije, ne biti škodljive za svog primatelja, te biti dobro poznate stručnjaku; vidjeti primjerice Remingtons Pharmaceutical Sciences, 19. izdanje, Mack Publishing Company, (1995.
and pharmaceutically acceptable enantiomers, diastereomers, racemates, and salts thereof. 
i njihovi farmaceutski prihvatljivi enantiomeri, diastereomeri, racemati i soli.
The antibody or antibody fragment thereof according to any one of claims 1 to 5 that is further conjugated to an effector molecule, wherein the effector molecule is preferably selected from the group consisting of heterologous polypeptides, drugs, radionucleotides, and toxins. 
Protutijelo ili njegov fragment protutijela prema bilo kojem od zahtjeva 1 do 5 naznačeno time da je nadalje konjugirano na efektorsku molekulu, pri čemu je efektorska molekula heterologni polipeptid, lijek, radionukleotid, ili toksin.
Compounds of the invention are selected from: 
Datum objave europskog patenta:
Preferred prodrugs consist of a compound of formula I where a pendant hydroxyl is phosphorylated to generate a phosphate derivative. 
Poželjni prolijekovi sastoje se od spoja formule I gdje je pripadajući hidroksil fosforiliran za dobivanje fosfatnog derivata.
The articulation portion may include a first articulation limb which is resiliently joined to a second articulation limb of the articulation portion at a join therebetween such that the first articulation limb may be moved from its quiescent position relative to the second articulation limb by resilient flexure and/or torsion of either limb and/or of the join therebetween. 
HR P20160751 T1 spoju tako, da prvi zglobni krak može biti pomaknut iz svojega mirnog položaja u odnosu na drugi zglobni krak, pomoću elastičnog pregibanja i/ili zavrtanja kraka i/ili međusobnog zglobnog spoja.
The present invention also provides the use of the dihydrogenphosphate salt of structural formula I or a hydrate thereof, in particular the crystalline monohydrate, for the manufacture of a medicament for the treatment of clinical conditions for which an inhibitor of DP-IV is indicated. 
Predmetni izum također daje korištenje dihirogenfosfatne soli strukturne formule I ili njenog hidrata, posebno kristalnog monohidrata za proizvodnju lijeka za liječenje kliničkih stanja za koje je indiciran inhibitor DP-IV.
mixing the pre-blended water soluble and/or water swellable coating material particles and substantially water insoluble polymer particles with core particles to produce the coated core particles. 
2) - miješanje prethodno sjedinjenih u vodi topivih materijalnih čestica, koje bubre u vodi, u vodi potpuno netopivih polimernih čestica s česticama jezgre radi stvaranja obloge osnovnih čestica.
The method according to clause 1, wherein the bicontinuous micro-emulsion contains at least 15 mM metal nanoparticles calculated on the aqueous phase. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što dvokontinualna mikroemulzija sadrži najmanje 15 mM metalnih nanočestica, obračunato na vodenu fazu.
An isolated antibody or fragment thereof that is capable of binding to a complex comprising B-Klotho and FGFR1c and induces FGF21-mediated signaling and comprises the following CDRs: 
Izolirano antitijelo ili njegov fragment koje je sposobno za vezanje za kompleks koji sadrži B-Klotho i FGFR1c i inducira FGF21-posredovani prijenos signala i sadrži sljedeće CDR regije:
A conjugate according to claim 9 or a use according to claim 10 for carrying drugs across the blood-brain barrier. 
Konjugat u skladu s patentnim zahtjevom 9 ili uporaba u skladu s patentnim zahtjevom 10 za prijenos lijekova kroz krvno-moždanu barijeru.
In one embodiment of the present invention, the crenolanib or a pharmaceutically acceptable salt thereof is provided at least one of sequentially or concomitantly, with another chemotherapeutic agent in a newly diagnosed proliferative disease, to maintain remission, or a relapsed/refractory proliferative disease. 
Pripravak namijenjen uporabi u skladu s patentnim zahtjevom 13, pri čemu se crenolanib ili njegova sol osigurava barem jednom slijedno ili istodobno s drugim kemoterapijskim agensom u novodijagnosticiranoj akutnoj mijeloičnoj leukemiji (AML), radi održavanja remisije ili relapsirane ili refraktorne akutne mijeloične leukemije (AML).
The blister pack according to claim 8, in which said top layer comprises at least a layer located above, and a layer located beneath, said aluminium layer. 
Blister pakiranje prema 8., naznačeno time da navedeni gornji sloj (6) sadrži najmanje još dva sloja (6p, 6c) koji se nalaze na suprotnim stranama navedenog aluminijskog sloja (6).
The antibody for use according to claim 27, the use according to claim 29 or the method according to claim 31, wherein the cancer is selected from the group consisting of breast cancer, prostate cancer, bone cancer, colorectal cancer, leukaemia, lymphoma, skin cancer, esophageal cancer, gastric cancer, astrocytic cancer, endometrial cancer, cervical cancer, bladder cancer, renal cancer, lung cancer, liver cancer, thyroid cancer, head and neck cancer, pancreatic cancer and ovarian cancer. 
Antitijelo za upotrebu prema patentnom zahtjevu 11 naznačeno time da je rak odabran iz skupine koja se sastoji od raka dojke, raka prostate, raka kostiju, kolorektalnog raka, leukemije, limfoma, raka kože, raka jednjaka, raka želuca, astrocitnog raka, raka endometrijuma, raka vrata materice, raka mokraćnog mjehura, raka bubrega, raka pluća, raka jetre, raka štitnjače, raka glave i vrata, raka gušterače i raka jajnika.
A system for determining a displacement of an anchor (1), the system comprising 
Sustav za određivanje pomaka sidra (1), koji obuhvaća
obtaining the heterodimeric antibody. The method according to claim 1, wherein step b) comprises subjecting at least 10 mL of the composition obtained from step a) to oxidizing conditions sufficient to allow oxidation. 
podvrgavanje najmanje 10 mL od sastava koji je dobiven u koraku a) uvjetima oksidacije koji su dovoljni za omogućavanje oksidacije cisteina u bispecifičnom protutijelu pune duljine za međulančane disulfidne veze; i
an antibody or antigen binding portion thereof, that specifically binds to and neutralizes C. difficile toxin B. 
antitijelo ili njegov dio koji se veže za antigen, koje se specifično veže za i neutralizira C. difficile toksin B.
The solid composition of claim 12, used for the evaluation of right colon adenomas, right colon polyps and/or interval cancers. 
Čvrsti pripravak u skladu s patentnim zahtjevom 12, naznačen time što se upotrebljava kod procjenjivanja adenoma desnog debelog crijeva, polipa desnog debelog crijeva i/ili intervalnih rakova.
represents aluminium, magnesium, zinc, or lithium; R1 represents a linear or branched C1-C20 alkyl group; m is 1, 2 or 3; 
- M, predstavlja aluminij, magnezij, cink, litij; RI predstavlja linearnu ili razgranatu C;-C2g alkil grupu; m je 1, 21li 3;
Determining whether If penetration occurs during excavation in step 3, the 
Ako dođe do penetracije tijekom bušenja u koraku 3, pulpa je pogođena
An in vitro method of determining whether an individual has or is at risk of a condition wherein the condition is characterized by allergic symptoms in response to a cat allergen, the method comprising testing whether the individual has T cells which respond to a composition as defined in any one of claims 1 to 5, thereby determining whether the individual has or is at risk of the condition. 
In vitro metodu utvrđivanja da li pojedinac ima ili je u opasnosti od stanja u kojem je, naznačena time, što je stanje karakterizirano sa alergijskim simptomima kao odgovor na alergene mačke, metoda se sastoji od testiranje da li pojedinac ima T stanice koje reagiraju na sastav kao što je definirano u bilo kojem od zahtjeva 1 do 5, čime bi se utvrdilo da li pojedinac ima ili je u opasnosti od stanja, t>&
The remainder of the composition may suitably consist of edible dry carrier materials, water, ethanol, lipids or any combinations thereof. 
Ostatak pripravka može prikladno uključivati jestive suhe nosače, vodu, etanol, lipide ili bilo koje njihove kombinacije.
A solution for use according to anyone of claims 6-12, wherein the treatment is in a patient having a chronic lung disorder. 
Vodena otopina za uporabu sukladno patentnom zahtjevu 13, pri čemu pacijent pati od kroničnog poremećaja pluća.
The organic layer discarded and aqueous layer freeze dried to afford 43 (16.3 g, 66%) as pale yellow powder. 
Organski sloj je odbačen i vodeni sloj je osušen zamrzavanjem da bi se dobio spoj 43 (16.3 g, 66%) kao blijedo žuti prašak.
(c.) a group of the formula or (d.) ring AH, wherein ring AH is C3-C6 cycloalkyl or phenyl, wherein ring AH is unsubstituted or substituted by 1 to 3 moieties independently selected from halo or C1-C3 alkyl. 
(c.) grupa formule [image] (d.) prsten AH, gdje je prsten AH C3-C6 cikloalkil ili fenil, pri čemu je prsten AH nesupstituiran ili je supstituiran sa 1 do 3 komponente nezavisno odabrane između halo ili C1-C3 alkil.
Lyophilization process was performed as before for Formulations ET-NF A, ET-NF B and ET-NF F (Table IX). 
Proces liofilizacije je izveden kaoza prethodni slučaj za oblike ET-NF A, ET-NF B i ET-NF F (Tablica IX).
A composition according to any preceding claim, wherein the filler comprises a sugar alcohol, for example mannitol. 
Sastav prema zahtjevu 2, naznačen time, da punilo sadrži manitol kao šećerni alkohol.
Figure 1 is an exploded perspective view of a ski boot according to the invention; 
Na crtežima: slika 1 = prikazuje u perspektivi rastavljenu cipelu za skijanje prema izumu; slika 2
The system of claim 1 wherein the gettering system comprises one or more of a Titanium deposition system and a Lithium deposition system that coat the plasma facing surfaces of the confine chamber and the first and second divertors. 
Postupak prema zahtjevu 1, 4 do 5 i 7, naznačen time, da getter-sustav obuhvaća jedan ili više sustava deponiranja titana (810) 1 sustava deponiranja litija (820), koji oblažu površine okrenute prema plazmi od priključne komore i od prvog i drugog preusmjerivača.
The humanized antibody according to claim 1 having a variable heavy chain and a variable light chain comprising the amino acid sequences of SEQ ID NO:53 and SEQ ID NO:52, respectively. 
Humanizirano protutijelo, naznačeno time što ima teški lanac i laki lanac, koji imaju aminokiselinske sljedove SEQ ID NO:35 odnosno SEQ ID NO:31.
The polypeptide of any one of claims 1-9, wherein the polypeptide comprises an amino acid sequence according to SEQ ID NO:32 residues 1-567 or SEQ ID NO:66 residues 1-378. 
Polipeptid iz bilo kojeg od patentnih zahtjeva 1-9, gdje polipeptid sadrži aminokiselinsku sekvencu u skladu sa SEK ID BR:32 ostaci 1-567 ili SEK ID BR:66 ostaci 1-3758.
The compound according to claim 2, wherein R1 represents a hydroxyl-protecting group; R2 represents a hydroxyl-protecting group; and R3 represents a fluorine atom. 
Metoda prema patentnom zahtjevu 9, gdje R1a predstavlja po izboru supstituiranu benzoil grupu; i R2a predstavlja po izboru supstituiranu benzoil grupu.
the modified oligonucleotide comprises at least one phosphodiester internucleoside linkage. 
g sekvenca nukleobaza modificiranog oligonukleotida je:
Suitable diluents include, but are not limited to, starch (i.e. corn, wheat, or potato starch, which may be hydrolized), lactose (granulated, spray dried or anhydrous), sucrose, sucrose-based diluents (confectioner's sugar; sucrose plus about 7 to 10 weight percent invert sugar; sucrose plus about 3 weight percent modified dextrins; sucrose plus invert sugar, about 4 weight percent invert sugar, about 0.1 to 0.2 weight percent cornstarch and magnesium stearate), dextrose, inositol, mannitol, sorbitol, microcrystalline cellulose (i.e. AVICEL™ microcrystalline cellulose available from FMC Corp.), dicalcium phosphate, calcium sulfate dihydrate, calcium lactate trihydrate and the like. 
Farmaceutska dozna formulacija prema patentnom zahtjevu 5, naznačena time što je diluent izabran iz grupe koju čine škrob; laktoza; saharoza; diluenti na bazi saharoze kao što je konditorski šećer, saharoza sa dodatkom 7 do 10 masenih postotaka invertnog šećera, saharoza sa dodatkom oko 3 masena postotka modificiranih dekstrina; saharoza sa dodatkom invertnog šećera, oko 4 masena postotka invertnog šećera, 0.1 do 0.2 masena postotka kukuruznog škroba i magnezij stearata; dekstroza; inozit; manitol; sorbitol; mikrokristalna celuloza; dikalcij fosfat; kalcij sulfat dihidrat; i kalcij laktat trihidrat.
The aesthetic imaging and treatment system (20) according to any one of the preceding claims, wherein the first layer of tissue and the second layer of tissue are located at different depths below a single region of a skin surface to increase the overall volume of tissue treated below said skin surface, thereby providing an enhanced overall cosmetic result. 
Sustav za kozmetičko snimanje i liječenje (20) u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time, da se prvi sloj tkiva 1 drugi sloj tkiva nalaze na različitim dubinama ispod jednog samog područja površine kože čime se povećava ukupni volumen tretiranog tkiva ispod navedene površine kože, pružajući time poboljšani ukupni kozmetički rezultat.
A DAPTZ compound for use as claimed in any one of claims 1 to 3 wherein the cognitive or CNS disorder is selected from: 
DAPTZ-spoj u stabilnom, kristalnom, reduciranom obliku za uporabu prema bilo kojem od prethodnih zahtjeva, naznačen time, da kognitivni poremećaj ili CNS poremećaj je odabran od sljedećih:
The antibody according to any one of claims 1 to 7, wherein the antibody does not inhibit EPHA2 ligand binding to EPHA2 but inhibits the phosphorylation of EPHA2 tyrosine residues induced by the ligand. 
Antitijelo u skladu sa bilo kojim od patentnih zahtjeva 1 do 6, gdje antitijelo ne inhibira vezivanje EPHA2 liganda za EPHA2 ali inhibira fosforilaciju EPHA2 tirozinskih ostataka induciranu pomoću liganda.
admixing the ozonated emulsion with solid particulate ammonium nitrate to absorb the emulsion into the ammonium nitrate, thereby to form an ammonium nitrate/fuel oil explosive. 
* > primješavanje u ozoniranu emulziju krutih čestica amonijevog nitrata da se emulzija absorbira u amonijevom nitratu, te se tako dobiva eksploziv na bazi amonijevog nitrata/loživog ulja.
The compound of any one of claims 1 to 3, the conjugate of claim 6 or 7, the nucleic acid molecule or the set of nucleic acid molecules according to claim 8, the vector or the set of vectors of claim 9, or a pharmaceutical composition according to claim 11, for use in treating, ameliorating, or preventing a bleeding disease or disorder in a subject in need thereof. 
Spoj prema bilo kojem od zahtjeva 1 do 3, konjugat prema zahtjevu 6 ili 7, molekula nukleinske kiseline ili set molekula nukleinske kiseline prema zahtjevu 8, vektor ili set vektora prema zahtjevu 9, ili farmaceutski pripravak prema zahtjevu 11, za uporabu u liječenju, ublažavanju ili prevenciji bolesti ili poremećaja krvarenja kod subjekta kojemu je to potrebno.
The method of claim 9, wherein at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% of said transposome complexes in solution comprise a second tag comprising a second tag domain. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 7-9, naznačen time što najmanje 50 %, 55 %, 60 %, 65 %, 70 %, 75 %, 80 %, 85 %, 90 %, 95 %, 96 %, 97 %, 98 %, 99 % navedenih transposomskih kompleksa u otopini sadrži drugi biljeg, koji sadrži drugu bilježnu domenu.
The stitches of the second rows of knitting 2 are provided by means of the same needles for the various second rows of knitting 2, thus obtaining rib knitting. 
Očice parnih redova pletiva 2 izrađene su pomoću istih igala za različite parne redove pletiva 2, čime se dobije rebrasto pletenje.
Preferably the amount of PA residues that are present in the triglycerides are below 30 wt.%, more preferably between 16 and 24 %. 
HR P20161271 T1 površini, količina fosfolipida prisutnih u nutritivnom pripravku je od 0.5 do 20 tež.% fosfolipida u odnosu na ukupne lipide.
A microfluidic device according to claim 2 characterised in that said microfluidic channels (6a, 6b) are capillary channels, wherein the surfaces of said channels are hydrophilic and capillarity acts as the only force for moving the fluid medium. 
Mikrofluidički uređaj u skladu s patentnim zahtjevom 2, naznačen time što navedeni mikrofluidički kanali (6a, 6b) su kapilarni kanali, gdje površine navedenih kanala su hidrofilne, a kapilarnost je jedina pogonska sila za fluidni medij.
The pump 29 associated with the first water reservoir 1 supplies pressurised water to the inlet 23 of a first thermoblock 4, while the pump 30 being associated with the second water reservoir 2 supplies pressurised water to the inlet 24 of the second thermoblock 3. 
Pumpa 29, povezana s prvim spremnikom za vodu 1, dobavlja vodu pod tlakom na ulaz 23 prvog termobloka 4, dok pumpa 30, povezana s drugim spremnikom za vodu 2, dobavlja vodu pod tlakom na ulaz 24 drugog termobloka 3.
culturing the one or more mammalian cells in the copper supplemented cell culture media such that rA13 is expressed and excreted from the cells into a culture supernatant, wherein the culturing comprises continuous cultivation; and 
kultiviranje jedne ili više stanica u mediju sa staničnoj kulturi dopunjenoj bakrom, tako da se rVWF eksprimira i izluči iz stanica u supernatant kulture, pri čemu se sadržaj NH4+ u supernatantu stanične kulture održava u koncentraciji ispod 4 mM; i
Thus the invention also provides compounds of formula (I) and pharmaceutically acceptable salts thereof for use as a therapeutic substance, in particular in the treatment of conditions or disorders mediated via the GPR38 receptor. 
Upotreba spoja prema bilo kojem od zahtjeva 1 do 7, ili njegove farmaceutski prihvatljive soli, naznačena time što se upotrebljava za proizvodnju lijeka za upotrebu u liječenju stanja ili poremećaja putem receptora GPR38.
A pharmaceutical composition comprising a compound according to claim 1 and a therapeutically inert carrier. 
Farmaceutski sastav, naznačen time, da obuhvaća spoj prema bilo kojem od zahtjeva 1 do 13, i terapeutski inertan nosač.
A ship according to claim 13, characterized in that the purification unit (2") comprises a third connecting means (K3") for connecting it to a pressurized air circuit of the ship so as to enable pressurized air to be applied to a clean side of the membrane filter. 
Brod prema zahtjevu 13, naznačen time da jedinica za pročišćavanje (2") sadrži treća spojna sredstva (K3") za spajanje s brodskim krugom stlačenog zraka tako da omogućava da se stlačeni zrak primjenjuje na čistu stranu membranskog filtera.
Conveniently the reaction is carried out in a suitable inert organic solvent, for example isopropanol, dioxane or N,N -dimethylacetamide. 
Prikladno se reakcija provodi u prikladnom inertnom organskom otapalu poput primjerice izopropanaola, diokasana ili N.N-dimetilacetamida.
The indexed drug containment device of claim 8, wherein the radio frequency identification device is disposed about a neck of the canister. An indexed drug actuation device for use in an indexed drug delivery and regulation device comprising: 
Indeksirani uređaj za ograničavanje sadržaja lijeka (24) prema zahtjevu 6, naznačen time da je radio frekvencijski identifikacijski uređaj (50) smješten oko grlića spremnika (28).
A multicomponent microbicidal contraceptive intravaginal ringed-mesh device as in claim 2 wherein the ring matrix contains at least one contraceptive agent and wherein the polymeric coating contains at least one bioactive agent. 
što vlaknasta mrežica sadrži poliester, što matriks prstena sadrži najmanje jedno kontraceptivno sredstvo, te što polimerna obloga sadrži najmanje jedno od navedenih bioaktivnih sredstava.
As the thermo-sealable plastic coating is melted prior to inserting the cup in the shell they will be bonded in the corresponding bonding spots and/or bonding areas by this coating after it has cooled and hardened. 
Budući da se obloga od plastike, koja plastika se lijepi kada je vruća, rastopi prije umetanja čaše u ljusku, 1 čaša 1 ljuska će tada biti, nakon što se obloga stvrdne, spojeni na odgovarajućim točkama spajanja i/ili na predjelima spajanja pomoću te obloge.
The process according to claim 1, wherein the R functional group(s) of the hydrophobically modified polyalkyleneimine are a C1 to C32 fatty amide(s). The process according to claim 1, wherein the R functional group(s) of the hydrophobically modified polyalkyleneimine are a C5 to C18 fatty amide(s). 
Proces prema bilo kojem od zahtjeva 1 do 13, naznačen time što je (su) R funkcionalne skupine tog hidrofobno modificiranog polialkilenimin C1 do C32 masni amid(i), poželjnije C5 do C18 masni amid(i), i najpoželjnije C5 do C14 linearni masni amid(i).